Pathways’ Picks April 7: Brazil Spotlights Stent Prices, Swixit Prep, Prior Auth Pushback

article image

In this week’s roundup: Brazil launches its new implantable device price monitoring database, starting with coronary stents; Switzerland and the EU take steps to soften the short-term blow of not reaching a bilateral agreement before the Medical Device Regulation takes effect; groups push CMS to delay its plans to expand prior authorization in Medicare; and more news from Europe and the US.

Top Pick: Brazil Spotlights Stent Prices

After years in development, Brazil launched a public price benchmarking database for implantable devices April 1. The first devices to be put under the limelight in the database are coronary stents, both bare-metal and drug-eluting. The database is intended to help counter a history of corruption linked to overinflated pricing for implantable devices in the country. It lists reference prices, with quartile ranges, for stents with different technical attributes, based on a combination of list price information the manufacturers submit to ANVISA as part of the regulatory registration process and public procurement information. The government is not imposing any price controls on the products—the information is intended to improve transparency so hospitals are at greater advantage in procurement negotiations. (See “Brazil Device Price Database Plan Starts to Take Form,” Market Pathways, August 7, 2020.)

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: